Renowned ENT surgeon Prof. Paul Van de Heyning argues that low frequencies, long electrodes, and anatomy-based fitting can reshape cochlear implant care. Find the key messages of his lecture at Johns Hopkins University School of Medicine in this article—and watch the embedded recording of his presentation for full information.

OTOGUIDE: Precision you can see. You know OTOPLAN,* OTODRIVE,** and OTOARM. And now there’s OTOGUIDE, our new intraoperative software that enables you to see electrode array insertion like never before.

MED-EL has focused decades of research on residual hearing preservation. While remaining hearing is often limited to specific frequency ranges, preserving residual hearing can improve hearing outcomes with a cochlear implant.

A cochlear implant electrode serves not only as a crucial bridge between technology and nature that connects recipients to sound. The electrode array can significantly impact hearing outcomes. For instance, there is now growing consensus among researchers that stimulating more of the cochlea is associated with better speech perception and music appreciation. Here is the latest research you need to know to ensure each of your patients can benefit the most from their cochlear implant.

The active, transcutaneous BONEBRIDGE BCI 602 implant offers clear advantages over percutaneous BAHA (bone-anchored hearing aid) implants. Time and again, BAHAs are explanted and replaced with BONEBRIDGE. Leading ENT surgeons have reached an international consensus and established guidelines for the explantation of a BAHA followed by implantation of BCI 602.

We just revealed our latest innovations at CI2024 in Las Palmas de Gran Canaria, Spain. There we unveiled new tools to enable clinicians to provide follow-up fitting care remotely to MED-EL cochlear implant users without an appointment. We also offered a sneak peek into what’s coming soon for cochlear implantation and RONDO 3 users.